Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia.

Parkinson's Disease
Sylvia Navailles, Philippe De Deurwaerdère

Abstract

L-DOPA-induced dyskinesias (LIDs) are one of the main motor side effects of L-DOPA therapy in Parkinson's disease. The review will consider the biochemical evidence indicating that the serotonergic neurons are involved in the dopaminergic effects of L-DOPA in the brain. The consequences are an ectopic and aberrant release of dopamine that follows the serotonergic innervation of the brain. After mid- to long-term treatment with L-DOPA, the pattern of L-DOPA-induced dopamine release is modified. In several brain regions, its effect is dramatically reduced while, in the striatum, its effect is quite preserved. LIDs could appear when the dopaminergic effects of L-DOPA fall in brain areas such as the cortex, enhancing the subcortical impact of dopamine and promoting aberrant motor responses. The consideration of the serotonergic system in the core mechanism of action of L-DOPA opens an important reserve of possible strategies to limit LIDs.

References

Jun 1, 1991·Molecular and Chemical Neuropathology·K A Jellinger
Jun 1, 1990·British Journal of Pharmacology·N B MercuriG Bernardi
May 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·D ScholsE De Clercq
Sep 23, 1988·European Journal of Pharmacology·J YamadaK Horisaka
Sep 26, 1973·Nature: New Biology·S R Levinson, J C Ellory
Jul 1, 1972·Neurology·L K NgI J Kopin
Mar 14, 1968·The New England Journal of Medicine·H Levine
Mar 14, 1968·The New England Journal of Medicine·G C Cotzias
Dec 1, 1968·European Journal of Pharmacology·U Ungerstedt
Jun 1, 1984·The Journal of Comparative Neurology·F W Schürmann, N Klemm
Jan 1, 1995·Neuroscience and Biobehavioral Reviews·R M Kostrzewa
Jan 1, 1995·European Archives of Psychiatry and Clinical Neuroscience·K Ikeguchi, A Kuroda
Oct 1, 1993·Clinical Neuropharmacology·B Gomez-Mancilla, P J Bédard
Apr 1, 1996·The American Journal of Psychiatry·S Kapur, G Remington
Jan 1, 1997·Movement Disorders : Official Journal of the Movement Disorder Society·A AntoniniK L Leenders
Mar 1, 1997·Neurology·J M GorellR J Richardson
Jun 17, 1998·Brain Research·M E CastroA Pazos

❮ Previous
Next ❯

Citations

Jul 22, 2014·Progress in Neuro-psychopharmacology & Biological Psychiatry·Nicolas MorinThérèse Di Paolo
Sep 10, 2014·Expert Opinion on Drug Safety·Giovanni FalisiRaul Quezada Arcega
Aug 10, 2015·Neuropharmacology·Nicolas MorinThérèse Di Paolo
May 9, 2012·Revue neurologique·P De Deurwaerdère, S Navailles
Mar 26, 2016·Progress in Neurobiology·Philippe De Deurwaerdère, Giuseppe Di Giovanni
Jul 26, 2015·Progress in Neurobiology·Matthieu F BastideErwan Bézard
May 31, 2013·Progress in Neuro-psychopharmacology & Biological Psychiatry·Maria Gabriela SánchezThérèse Di Paolo
Jul 9, 2016·Progress in Neurobiology·Philippe De DeurwaerdèreMark J Millan
Jul 25, 2019·Movement Disorders : Official Journal of the Movement Disorder Society·Laura BoiAnna R Carta
Jan 8, 2020·International Journal of Molecular Sciences·Abdeslam ChagraouiPhilippe De Deurwaerdère
Apr 24, 2020·Frontiers in Pharmacology·Elena Paredes-RodriguezCristina Miguelez
Aug 8, 2020·Frontiers in Neurology·Yannick VermeirenPeter P De Deyn
Dec 10, 2016·Frontiers in Neuroscience·Giuseppe Di GiovanniPhilippe De Deurwaerdère
Sep 29, 2017·Frontiers in Cellular Neuroscience·Cristina MiguelezPhilippe De Deurwaerdère
May 7, 2021·Journal of Experimental Pharmacology·Andrea Fabbrini, Andrea Guerra

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.